profit from every $100 of sales.
$0$100
Kyverna Therapeutics
$5.05+0.40% today
-22.1% in 1 year
1-year low $4.611-year high $11.25
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Kyverna Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $7.03 million in 2022 to $0 in 2025, with -$161 million of profit last year.
SalesProfit
Kyverna Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Kyverna Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Kyverna Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 7 | 0 | 0 | 0 | |
| – | – | – | – | |
| -29 | -62 | -143 | -170 | |
| -28 | -58 | -125 | -159 | |
| -29 | -60 | -127 | -161 | |
| -1.12 | -1.48 | -3.33 | -3.64 | |
| – | – | – | – | |
| -418.3% | – | – | – | |
| -411.3% | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 67 | 75 | 305 | 294 |
| Cash | 38 | 35 | 97 | 124 |
| Total debt | 11 | 9 | 8 | 29 |
| Total liabilities | 141 | 207 | 38 | 62 |
| -74 | -131 | 267 | 232 | |
| 26 | 41 | 38 | 44 | |
| – | – | -36.6% | -48.6% | |
| 39.0% | 45.9% | -47.8% | -69.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -36 | -52 | -114 | -154 | |
| 1 | 1 | 2 | 1 | |
| -37 | -53 | -116 | -155 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 2 | 8 | 10 |
Valuation
- –
- –
- –
- 2.7×
- 44.5×
- –
- –
- -11.8%
- -9.3%
- 0.0%
Profitability
- 0.0%
- -418.3%
- -411.3%
- 0.0%
- -71.4%
- -39.5%
- -81.9%
- -60.9%
- -72.0%
- –
Growth
- –
- –
- −32.0%
- –
- +14.4%
Financial health
- -1.0×
- 0.05
- 3.5%
- -144.7×
- 8.15
- 8.15
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 2%of 952
Bottom 9%of 987
What analysts expect
- Average price target
- $32.67
- Range
- $32.00 – $33.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.66 | -0.75 | +12.0% |
| Mar 26, 2026 | -0.80 | -0.85 | +5.3% |
| Nov 12, 2025 | -0.85 | -0.97 | +12.4% |
| Aug 12, 2025 | -0.97 | -1.00 | +3.0% |
| May 13, 2025 | -1.03 | -1.21 | +14.9% |
| Mar 27, 2025 | -0.88 | -0.87 | −1.1% |
| Nov 13, 2024 | -0.80 | -0.77 | −3.9% |
| Aug 12, 2024 | -0.67 | -0.70 | +4.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
44No pass
Philip Fisher
34No pass
Peter Lynch
49No pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
30No pass
Questions about Kyverna Therapeutics
Is Kyverna Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Kyverna Therapeutics AI analysis
What does Kyverna Therapeutics do?
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. It is in Biotechnology.
Does Kyverna Therapeutics pay a dividend?
No. Kyverna Therapeutics does not pay a dividend at the moment.
Is Kyverna Therapeutics stock halal?
No. Kyverna Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 40% of its market value, at or above the 33% limit. How we check
How has Kyverna Therapeutics stock done over the past year?
Down 22.1% over the past twelve months, to $5.05. It traded between $4.61 and $11.25 and is 55.1% below its high.
Who are Kyverna Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Kyverna Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.